Loading...
XKRX
137310
Market cap765mUSD
Dec 05, Last price  
9,430.00KRW
1D
1.07%
1Q
-7.00%
IPO
-84.04%
Name

SD Biosensor Inc

Chart & Performance

D1W1MN
XKRX:137310 chart
P/E
P/S
1.62
EPS
Div Yield, %
Shrs. gr., 5y
3.53%
Rev. gr., 5y
56.94%
Revenues
694.57b
+5.93%
65,633,389,42372,962,238,0001,686,163,033,2702,929,960,839,8802,932,001,440,300655,676,513,230694,573,795,000
Net income
-98.41b
L-78.96%
3,031,673,9833,153,182,350615,635,988,7401,088,470,714,180911,362,364,420-467,711,537,230-98,410,898,000
CFO
156.53b
P
-962,540,480-1,624,776,770495,381,692,5501,234,945,051,190890,233,362,780-242,318,512,830156,526,985,000
Dividend
Dec 27, 2023290 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
IPO date
Jul 16, 2021
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT